Stroke Prevention in Atrial Fibrillation
Literature review: stroke prevention in atrial fibrillation
The review includes the pivotal randomised controlled trials for warfarin and direct oral anticoagulants as well as relevant publications from the last 18 months. The following search terms were used: ‘stroke prevention’, ‘atrial fibrillation’, dabigatran, rivaroxaban, apixaban, edoxaban, warfarin, ‘oral anticoagulants’, ‘non-VKA oral anticoagulants’, novel oral anticoagulants’, ‘direct oral anticoagulants’, ‘reversal agents’
New This Month
-
Hugh Calkins, Stephan Willems, Atul Verma, et alCalkins H et al. EP Europace, euz057.
-
Robert A. Byrne, Roisin Colleran, Adnan Kastrati, et alByrne RA et al. EuroIntervention. 2019;14:e1793-e1795.
-
Noel C Chan, John W. EikelboomChan NC and Eikelboom JW. Blood. 2019. Epub ahead of print.
-
Khaji A, Hanley C, Peter R. Kowey, et alKhaji A et al. Cardiol Clin. 2019;37:197-206.
Videos
-
08 February 2019
-
08 February 2019
-
06 February 2019
-
06 February 2019
-
14 November 2018
-
14 November 2018
Pages
Webinars
-
Dr Robert Byrne, Prof Georg Nickenig, Prof Stefan Hohnloser, Prof Georg Nickenig, Prof Pepe Zamorano, Dr Jose Lopez-Sendon.
-
Gheorghe-Andrei Dan
-
Dr. Amit Mistri
Key Articles
-
Jason G Andrade, Nathaniel M. Hawkins, Christopher B. Fordyce, et alAndrade JG al. Can J Cardiol. 2018. Article in press.
-
Deirdre A Lane, Juliane Meyerhoff, Ute Rohner, et alLane DA et al. Clin Cardiol. 2018;41:855-861. 12 June, 2018. Epub ahead of print.
-
Christina Ji-Young Lee, Thomas Alexander Gerds, Nicholas Carlson, et alLee CJ et al. J Am Coll Cardiol. 2018;72:17-26.
-
Stefan H Hohnloser, John W. EikelboomHohnloser SH and Eikelboom JW. J Am Coll Cardiol. 2018;72:27-28.
Independent Medical Education
-
Byrne R, Hohnloser S, Nickenig G, Sendon JL and Zamarano JL, Radcliffe-CME, Feb 2018.
-
Harald Darius
-
Hugh Calkins, A John Camm
-
Richard Hobbs
Guidelines/ Expert Recommendations
-
Gheorghe-Andrei Dan, Konstantinos Iliodromitis, Daniel Scherr, et alDan GA et al. Europace. 8 June, 2018. Epub ahead of print.
-
J. Steffel, Peter Verhamme, Tatjana S Potpara, et alSteffel J et al. Eur Heart J. 17 March, 2018. Epub ahead of print.
Randomised Controlled Trials
-
Stefan H Hohnloser, John W. EikelboomHohnloser SH and Eikelboom JW. J Am Coll Cardiol. 2018;72:27-28.
-
Emily C. O'Brien, DaJuanicia N. Holmes, Laine Thomas, et alO’Brien EC et al. J Am Heart Assoc. 2018;7:pii: e006391.
-
Luigi Di Biase, Jorge RomeroDi Biase L and Romero J. JACC Clin Electrophysiol. 2018;4:601-603.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Dabigatran
-
Stefan H Hohnloser, John W. EikelboomHohnloser SH and Eikelboom JW. J Am Coll Cardiol. 2018;72:27-28.
-
Stephan Glund, Guanfa Gan, Viktoria Moschetti, et alGlund S et al. Clin Appl Thromb Hemost. 1 January, 2018: 1076029618755947. Epub ahead of print.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Edoxaban
-
The Medical Letter, Inc. Med Lett Drugs Ther. 2018;60:99-101.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Apixaban
-
The Medical Letter, Inc. Med Lett Drugs Ther. 2018;60:99-101.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Diabetes
-
David A. McAllister, Stephanie Read, Jan Kerssens, et alCIRCULATIONAHA.118.034986. Epub ahead of print.
-
Michael E Nassif, Mikhail KosiborodNassif ME and Kosiborod M. Circulation. 2018;138:4-6.
-
Shilpa Vijayakumar, Muthiah Vaduganathan, Javed Butler, et alVijaykumar S et al. Circulation. 2018;137:1060-1073.
-
Petar M Seferovic, Mark C. Petrie, Gerasimos Filippatos, et alSeferović PM et al. Eur J Heart Fail. 8 March, 2018. Epub ahead of print.
Post-Hoc/Subgroup Analysis Of Pivotal Trials - Elderly
-
Giuseppe Patti, Ilaria Cavallari, Olivier Hanon, et alPatti G et al. Int J Cardiol. 2018;265:118-124.
-
Satoshi Yanagisawa, Yasuya Inden, Aya Fujii, et alYanagisawa S et al. JACC Clin Electrophysiol. 2018;4:592-600.
Stroke prevention in atrial fibrillation
Despite the evidence-based guidelines for the management of atrial fibrillation (AF), serious gaps continue to exist between clinical knowledge and practice, leaving patients at risk for disabling strokes. It is estimated that up to 67% of AF-related strokes are preventable. The significant increase in mortality and functional impairment is even more alarming, compared to non-AF strokes.
Updated AF treatment guidelines recommend new oral anticoagulants (NOACs) over warfarin for stroke prevention except, in patients with moderate to severe mitral stenosis or a mechanical heart valve. Based on some recent trials, NOACs were superior to warfarin for the prevention of the composite of stroke and systemic embolism in patients with AF and an additional risk factor for stroke. Reversal agents are now also available for NOACs in patients for severe bleeding or emergency procedures.
With the increased utilization of NOACs, it is critical for the clinician to understand the clinical and practical usage of these agents in diverse patient populations and clinical situations.
-
Hugh Calkins, Stephan Willems, Atul Verma, et al
This study also suggests that the heparin units required to reach the desired ACT may be affected by the time from the last preprocedural dose of dabigatran.
AIMS : To describe heparin dosing requirements in patients who...
Calkins H et al. EP Europace, euz057. -
Noel C Chan, John W. Eikelboom
In this review, the authors illustrate common challenges with anticoagulant use in older patients by describing five clinical cases and discussing how they decide upon the most appropriate antithrombotic therapy in those clinical situations....
Chan NC and Eikelboom JW. Blood. 2019. Epub ahead of print. -
Khaji A, Hanley C, Peter R. Kowey, et al
In this editorial, Pokorney and Lopes consider screening for atrial fibrillation (AF)
Heart failure (HF) and atrial fibrillation (AF) are the epidemics of the twenty-first century. These often coexist and are the cause of major morbidity...
Khaji A et al. Cardiol Clin. 2019;37:197-206. -
Subodh Verma, John JV McMurray
The authors of this editorial refer to the latest publications from DECLARE-TIMI 58 and the CANVAS Program.
Diabetes intersects with cardiovascular disease at every level. While there has been much focus on understanding atherosclerotic...
Verma S and McMurray JJV. Circulation. 2019. Epub ahead of print. -
Eri T Kato, Michael G Silverman, Ofri Mosenzon, et al
In DECLARE-TIMI 58, the sodium glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin reduced the composite endpoint of cardiovascular (CV) death/ hospitalization for heart failure (HHF) in a broad population of patients with T2DM.
...
Kato ET et al. Circulation. 2019. Epub ahead of print.
-
10 Dec 2019
-
-
21 May 2019
-
21 May 2019
Videos
-
08 Feb 2019
-
08 Feb 2019
-
06 Feb 2019
-
06 Feb 2019
-
29 Nov 2018
Pages
Clinical publications
-
Javier Limeres, Bruno Garcia del BlancoLimeres J et al. Thromb Res. 2019;177:180-186.
-
Amgad Mentias, Alexandros Briasoulis, Ghanshyam Palamaner Subash Shantha, et alMentias A et al. Am J Cardiol. 2019. Epub ahead of print.
-
Nemin Chen, Pamela L. Lutsey, Richard F. MacLehose, et alJ Am Heart Assoc. 2018;7:e009561.
-
Jason G Andrade, Nathaniel M. Hawkins, Christopher B. Fordyce, et alAndrade JG al. Can J Cardiol. 2018. Article in press.
-
Deirdre A Lane, Juliane Meyerhoff, Ute Rohner, et alLane DA et al. Clin Cardiol. 2018;41:855-861. 12 June, 2018. Epub ahead of print.
Pages
Trials
-
Hugh Calkins, Stephan Willems, Atul Verma, et alCalkins H et al. EP Europace, euz057.
-
Laura Mauri, Gilles MontalescotLip GHY et al. Am Heart J. 2019;212:13-22.
-
Malini Madhavan, DaJuanicia N. Holmes, Jonathan P. Piccini, et alMadhavan M et al. Am Heart J. 2019;211:77-89.
-
Subodh Verma, John JV McMurrayVerma S and McMurray JJV. Circulation. 2019. Epub ahead of print.
-
Eri T Kato, Michael G Silverman, Ofri Mosenzon, et alKato ET et al. Circulation. 2019. Epub ahead of print.
Pages
Opinion articles
-
Robert A. Byrne, Roisin Colleran, Adnan Kastrati, et alByrne RA et al. EuroIntervention. 2019;14:e1793-e1795.
-
Khaji A, Hanley C, Peter R. Kowey, et alKhaji A et al. Cardiol Clin. 2019;37:197-206.
-
Sean D. Pokorney, Renato D. LopesPokorney SD and Lopes RD. Heart. 2019. Epub ahead of print.
-
Stefan H Hohnloser, John W. EikelboomHohnloser SH and Eikelboom JW. J Am Coll Cardiol. 2018;72:27-28.
-
Michael E Nassif, Mikhail KosiborodNassif ME and Kosiborod M. Circulation. 2018;138:4-6.
Pages
Review articles
-
Noel C Chan, John W. EikelboomChan NC and Eikelboom JW. Blood. 2019. Epub ahead of print.
-
Atul Verma, Subodh VermaCurr Opin Cardiol. 24 December, 2018. Epub ahead of print.
-
Giuseppe Patti, Ilaria Cavallari, Olivier Hanon, et alPatti G et al. Int J Cardiol. 2018;265:118-124.
Guidelines
-
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et alDas SR et al. J Am Coll Cardiol. November 2018. Epub ahead of print.
-
Gheorghe-Andrei Dan, Konstantinos Iliodromitis, Daniel Scherr, et alDan GA et al. Europace. 8 June, 2018. Epub ahead of print.
-
J. Steffel, Peter Verhamme, Tatjana S Potpara, et alSteffel J et al. Eur Heart J. 17 March, 2018. Epub ahead of print.
-
Petar M Seferovic, Mark C. Petrie, Gerasimos Filippatos, et alSeferović PM et al. Eur J Heart Fail. 8 March, 2018. Epub ahead of print.
